Ann: Immutep Quarterly Activities Report and Appendix 4C, page-20

So what is the point to just lay down some $100mil from their end and cut out half of the profit by the end?

not sure I understand what you mean re the above......

also...

part of fast track approval is convincing the FDA that you can service demand if approval granted....
ergo...HNC is a much smaller market than NSCLC by a long way, hence that's why immutep went the
way of HNC, with 2000 litre bioreactor upscaling due in the next 6 months for completion and storage
facilities already in place servicing demand for HNC has been deemed achievable if data comes up...

All my opinion but again I don't think immutep could convince the FDA they could service demand
for the vast lung cancer market...

Also in this regard, a successful HNC trial may lure Merck to take a bigger role in nsclc combo..